Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).
Lopez-Pascual A, Russo-Cabrera JS, Ardaiz N, Palmer T, Graham AR, Uriarte I, Gomar C, Ruiz-Guillamon D, Latasa MU, Arechederra M, Fontanellas A, Monte MJ, Marin JJG, Berasain C, Del Rio CL, Fernandez-Barrena MG, Martini PGV, Schultz JR, Berraondo P, Avila MA.
Lopez-Pascual A, et al. Among authors: schultz jr.
Clin Sci (Lond). 2024 Oct 16;138(20):1265-1284. doi: 10.1042/CS20241137.
Clin Sci (Lond). 2024.
PMID: 39301694